An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension

A Pilot, Open-Label, Controlled Clinical Trial of C-KAD Ophthalmic Solution in Reducing Intraocular Pressure in Patients With Ocular Hypertension

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00825396

Enrollment

Registered

2009-01-21

Start date

2007-04-30

Completion date

2009-04-30

Last updated

2009-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Hypertension

Brief summary

The purpose of this study is to determine the safety and tolerability of topical C-KAD Ophthalmic Solution in reducing intraocular pressure in patients with ocular hypertension.

Interventions

DRUGC-KAD Ophthalmic Solution

4 drops applied daily for 150 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Both eyes having intraocular pressure in the range of 22-30 mmHg at baseline * Both eyes having best corrected visual acuity better than 20/50

Exclusion criteria

* Advanced glaucoma * Closed or barely open anterior chamber or history of angle closure

Design outcomes

Primary

Measure	Time frame
Mean change in intraocular pressure from baseline	150 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026